Tecentriq (atezolizumab) is a prescription drug that’s used to treat certain cancers. The drug comes as a solution that your doctor will inject. It’s usually given on a cycle every 2, 3, or 4 weeks.

Evidence from a phase 3 trial does not support the addition of Tecentriq to a specific chemotherapy regimen with Avastin for patients with newly diagnosed stage 3 or 4 ovarian cancer. Adding Tecentriq ...

The FDA is anticipated to make its decision on the regimen by 9 October 2026.

Last year, Roche’s Tecentriq became the first immuno-oncology treatment approved in triple negative breast cancer after it showed it could stall cancer progression in combination with Celgene’s ...

– Pivotal Phase III IMbrave050 study investigating Tecentriq plus Avastin in people with early-stage hepatocellular carcinoma (HCC) at high risk of recurrence following surgery met primary endpoint of ...

– Phase III IMpower110 study showed Tecentriq monotherapy helped people with advanced non-small cell lung cancer (NSCLC) with high PD-L1 expression live longer compared with chemotherapy alone – – ...

Tecentriq combined with BCG did not enhance outcomes for high-risk NMIBC patients compared to BCG alone, with similar event-free survival rates. The ALBAN trial reported higher rates of side effects ...

Roche’s new immuno-oncology drug Tecentriq is ready for its close-up in lung cancer. The PD-L1 checkpoint inhibitor nabbed FDA approval for patients who’ve failed on a previous treatment, putting it ...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the Phase III IMbrave150 study, evaluating Tecentriq® ...

The FDA’s crackdown on drugs that aren’t meeting approval requirements has now hit Roche. The Swiss pharmaceutical giant announced Monday that it is pulling its blockbuster drug Tecentriq from the U.S ...

Add Yahoo as a preferred source to see more of our stories on Google. The submission is supported by data from the Phase III ATOMIC study. Credit: Gorodenkoff / Shutterstock.com. (Gorodenkoff / ...